INSM stock forecast, quote, news & analysis
Insmed Inc is a biopharmaceutical company... Show more
Insmed Incorporated (INSM) Stock Analysis: Pipeline Validation and Commercial Execution Define the Biotech's 2026 Trajectory
Key Takeaways
- Insmed shares closed at $106.92 on July 24, 2026, reflecting a modest 3.4% gain over the trailing 30-day period amid mixed sentiment across Wall Street.
- The company's commercial portfolio is anchored by two approved therapies — BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis and ARIKAYCE for refractory MAC lung disease — which together generated $306 million in first-quarter 2026 revenue.
- Two Phase 2b pipeline failures for brensocatib in hidradenitis suppurativa and chronic rhinosinusitis narrowed the drug's addressable market, contributing to a prolonged stock decline from its December 2025 peak above $212.
- Positive 12-month open-label extension data for TPIP in pulmonary arterial hypertension and the ENCORE Phase 3b success for ARIKAYCE have provided counterbalancing clinical catalysts.
- Analyst consensus remains a Strong Buy with an average price target near $199, though valuation debates persist given a price-to-sales ratio significantly above the biotech peer group.
Current Market Snapshot
Insmed Incorporated (INSM) has been trading in a volatile range throughout 2026, with shares oscillating between approximately $90 and $119 since January. The stock closed at $106.92 on July 24, representing a roughly 3.4% increase from the $103.38 level observed one month earlier. This relatively contained near-term movement belies the significant turbulence the stock has experienced year-to-date — INSM remains down nearly 40% in 2026 and trades roughly 48% below its 52-week high of $212.75 reached in early December 2025. The biotech sector broadly has performed well in the second quarter, with the Russell 2000 Growth Index gaining 25.6%, yet Insmed has lagged as investors weigh the commercial trajectory of BRINSUPRI against the lingering impact of pipeline disappointments earlier in the year.
Insmed Incorporated (INSM) Business Overview and Competitive Position
Insmed Incorporated is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's commercial foundation rests on two FDA-approved products. ARIKAYCE (amikacin liposome inhalation suspension) is approved for refractory Mycobacterium avium complex (MAC) lung disease and has been on the market since 2018, generating consistent year-over-year growth. BRINSUPRI (brensocatib), an oral reversible DPP1 inhibitor, launched in the U.S. in August 2025 for non-cystic fibrosis bronchiectasis — a chronic lung disease that had no previously approved pharmacological treatment — and received European Commission approval in November 2025.
Beyond its commercial portfolio, Insmed is advancing a deep pipeline led by treprostinil palmitil inhalation powder (TPIP), now in Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company's early-stage programs span gene therapy candidates for Duchenne muscular dystrophy and ALS, a second DPP1 inhibitor (INS1033) targeting rheumatoid arthritis and inflammatory bowel disease, and the recently acquired monoclonal antibody INS1148. Insmed's competitive positioning leverages its specialized focus on rare respiratory and inflammatory conditions where unmet medical need supports premium pricing and accelerated regulatory pathways.
Recent Developments Driving INSM
Several converging events have shaped Insmed's stock narrative over the past 30 days. In mid-July, the company released 12-month open-label extension data from its Phase 2b TPIP trial in pulmonary arterial hypertension, demonstrating sustained improvements across six-minute walk distance, NT-proBNP cardiac biomarkers, and WHO functional class. Stifel reiterated its Buy rating and $200 price target following the data, projecting peak TPIP sales exceeding $8 billion and calling the stock "intrinsically undervalued." BMO Capital initiated coverage on July 21 with an Outperform rating and a $192 target, highlighting BRINSUPRI's rapid launch trajectory and potential peak sales of $9.2 billion.
However, near-term headwinds persist. Clearbridge Investments noted in its Q2 2026 commentary that Insmed "gave up some of the prior year's strength driven by concerns around the pace of key drug Brinsupri's launch." Earlier in 2026, two Phase 2b programs evaluating brensocatib in hidradenitis suppurativa (CEDAR) and chronic rhinosinusitis without nasal polyps (BiRCh) failed to meet endpoints, triggering sharp selloffs and forcing discontinuation of both indications. Additionally, CEO William Lewis sold approximately $1.13 million in shares on July 23 under a pre-arranged 10b5-1 trading plan, a transaction that drew attention despite its planned nature. On the clinical front, the Phase 3b ENCORE study of ARIKAYCE in newly diagnosed MAC lung disease met all primary and secondary endpoints in March, positioning the company to submit an sNDA to the FDA in the second half of 2026 for a broader label expansion.
Trending AI Robots
For investors seeking data-driven approaches to navigate the volatility inherent in biotech stocks like Insmed, Tickeron's Trending AI Robots page offers a curated view of top-performing algorithmic trading strategies. Tickeron's platform hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across multiple timeframes and strategy types, but only the most relevant and highest-performing bots are featured in this section. Each bot operates with distinct methodologies — ranging from swing trading and trend following to pattern recognition and momentum-based approaches — allowing users to evaluate strategies based on historical performance metrics, win rates, and risk profiles. Exploring the Trending AI Robots page can provide a complementary perspective for those interested in systematic, algorithmically driven market participation.
2026 Outlook and What Investors Should Watch
The second half of 2026 presents a dense calendar of potential catalysts for Insmed. The company is scheduled to report second-quarter earnings on August 6, and investors will scrutinize BRINSUPRI's continued launch momentum — management reiterated 2026 revenue guidance of at least $1 billion for the drug. The open-label extension data from the Phase 2b TPIP PAH study is expected in the third quarter, and additional Phase 3 initiations for TPIP in progressive pulmonary fibrosis and idiopathic pulmonary fibrosis are anticipated by year-end. The planned sNDA submission for ARIKAYCE label expansion could meaningfully enlarge the drug's addressable patient population from roughly 30,000 to over 200,000 in the U.S. alone. Key risks include potential regulatory delays, evolving U.S. healthcare policy affecting drug pricing, competitive dynamics in the pulmonary space, and the company's ongoing path to profitability — management has guided for sustainable cash-flow positivity by 2027 without additional financing. With approximately $1.2 billion in cash and marketable securities as of March 31, Insmed maintains a financial runway to fund its expansive pipeline ambitions through this critical period.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsAroon Indicator for INSM shows an upward move is likely
INSM's Aroon Indicator triggered a bullish signal on July 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 221 similar instances where the Aroon Indicator showed a similar pattern. In of the 221 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on INSM as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for INSM just turned positive on August 06, 2026. Looking at past instances where INSM's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
INSM moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INSM crossed bullishly above the 50-day moving average on August 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for INSM moved out of overbought territory on August 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
INSM broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (36.364) is normal, around the industry mean (20.281). P/E Ratio (0.000) is within average values for comparable stocks, (25.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.845). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (23.866) is also within normal values, averaging (437.072).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology